<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241354</url>
  </required_header>
  <id_info>
    <org_study_id>ROSM-HO-001</org_study_id>
    <nct_id>NCT04241354</nct_id>
  </id_info>
  <brief_title>A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis</brief_title>
  <official_title>A Comparison of Platelet-rich Plasma Treatment to the Intra-articular vs. Intra- and Extra-articular Environments in Patients Diagnosed With Hip Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenerative Orthopedics and Sports Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EmCyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regenerative Orthopedics and Sports Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of one leukocyte-poor platelet-rich&#xD;
      plasma (LP-PRP) injection to the intra-articular (IA) space in comparison to one LP-PRP&#xD;
      injection to the IA space with an additional injection into the surrounding extra-articular&#xD;
      (EA) structures for the treatment of hip OA (Kellgren Lawrence Grades 1-3). Our hypothesis is&#xD;
      that patients receiving both IA and EA LP-PRP injections will have equivalent improvements on&#xD;
      HOOS JR and VAS scores over a 12-month period compared to those in the active comparator&#xD;
      group (IA LP-PRP injection).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A novel comprehensive approach through which the joint and its surrounding structures are&#xD;
      treated as an integrated system may offer a clinically superior treatment to hip&#xD;
      osteoarthritis (OA) compared to only an intra-articular (IA) infiltration. The efficacy of&#xD;
      autologous leukocyte-poor platelet-rich plasma (LP-PRP) for the treatment of OA is a growing&#xD;
      area of regenerative orthopedic research.&#xD;
&#xD;
      The purpose of this study is to determine if a LP-PRP treatment to both the IA space and EA&#xD;
      supporting capsular ligament and tendon structures provides a significant clinical benefit&#xD;
      when compared to an IA treatment alone. In this clinical study of 84 patients, both study&#xD;
      arms receive effective treatments that are supported by sound medical evidence, making this&#xD;
      an ethically strong model to address our hypothesis.&#xD;
&#xD;
      This is a multi-site, randomized, comparative study of LP-PRP treatment into the IA space&#xD;
      versus the IA space and EA hip structures. This study is sponsored by Regenerative&#xD;
      Orthopedics and Sports Medicine (ROSM) and EmCyte Corporation. Patients who meet the study&#xD;
      criteria with at least mild pain as indicated by &gt;25/100 on a 100mm visual analogue scale&#xD;
      (VAS) (Sanchez et al. 2011), or &lt;80/100 on HOOS JR with radiographic evidence of&#xD;
      Kellgren-Lawrence grades 1-3 hip OA will be invited to participate in this study.&#xD;
&#xD;
      The preparation of PRP is a simple tissue fractionation using centrifugation with EmCyte&#xD;
      PurePRP Supraphysiologic SP kit [EmCyte Corp. Fort Myers FL]. Platelet quantification&#xD;
      analysis is performed using the Horiba ABX Micros ES 60 [Plymouth Medical]. Primary outcome&#xD;
      measures are indicated by overall hip pain severity by HOOS JR and VAS patient reported&#xD;
      outcome measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">August 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hip Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)</measure>
    <time_frame>baseline</time_frame>
    <description>This is a patient-reported outcome measure for which scores range from 0 to 100 with a score of 0 indicating total hip disability and 100 indicating optimal hip health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>baseline</time_frame>
    <description>This is a patient-reported outcome measure. Scores range from 0 to 10 with score of 0 indicating no pain and a score of 10 indicating most intense pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>This is a patient-reported outcome measure. Scores range from 0 to 10 with score of 0 indicating no pain and a score of 10 indicating most intense pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>4 months</time_frame>
    <description>This is a patient-reported outcome measure. Scores range from 0 to 10 with score of 0 indicating no pain and a score of 10 indicating most intense pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>6 months</time_frame>
    <description>This is a patient-reported outcome measure. Scores range from 0 to 10 with score of 0 indicating no pain and a score of 10 indicating most intense pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Rating Scale</measure>
    <time_frame>12 months</time_frame>
    <description>This is a patient-reported outcome measure. Scores range from 0 to 10 with score of 0 indicating no pain and a score of 10 indicating most intense pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hip Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>This is a patient-reported outcome measure for which scores range from 0 to 100 with a score of 0 indicating total hip disability and 100 indicating optimal hip health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hip Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)</measure>
    <time_frame>4 months</time_frame>
    <description>This is a patient-reported outcome measure for which scores range from 0 to 100 with a score of 0 indicating total hip disability and 100 indicating optimal hip health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hip Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)</measure>
    <time_frame>6 months</time_frame>
    <description>This is a patient-reported outcome measure for which scores range from 0 to 100 with a score of 0 indicating total hip disability and 100 indicating optimal hip health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hip Osteoarthritis Outcome Score for Joint Replacement (HOOS JR)</measure>
    <time_frame>12 months</time_frame>
    <description>This is a patient-reported outcome measure for which scores range from 0 to 100 with a score of 0 indicating total hip disability and 100 indicating optimal hip health.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Osteoarthritis</condition>
  <condition>Degeneration</condition>
  <arm_group>
    <arm_group_label>Intra-articular LP-PRP Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra- and extra- articular LP-PRP Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of LP-PRP will be administered to the intra- articular space and the extra- articular structures under ultrasound guidance at the first visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Leukocyte-poor platelet rich plasma</intervention_name>
    <description>Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation [EmCyte Corp. Fort Myers FL].</description>
    <arm_group_label>Intra- and extra- articular LP-PRP Injection</arm_group_label>
    <arm_group_label>Intra-articular LP-PRP Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. Symptomatic OA of hip (K-L Grade 1-3) documented by x-ray taken within the past 6&#xD;
             months&#xD;
&#xD;
          2. Male or female age 30 - 65 at time of enrollment&#xD;
&#xD;
          3. Patients must have adequate immune system function with no known immunodeficiency&#xD;
&#xD;
          4. disease&#xD;
&#xD;
          5. Has not had a corticosteroid injection in the past 6 months&#xD;
&#xD;
          6. Has not used non-steroidal anti-inflammatory 7 days prior to treatment and has not&#xD;
             used oral&#xD;
&#xD;
          7. corticosteroids 30 days prior to treatment&#xD;
&#xD;
          8. If on chronic anticoagulant medication, we will follow the recommendations of the&#xD;
             physician&#xD;
&#xD;
          9. managing their anticoagulant medication&#xD;
&#xD;
         10. Willing and able to participate for the entire study period&#xD;
&#xD;
         11. No evidence of current systemic infection or illness (eg. fever, malaise, etc.) and no&#xD;
             evidence&#xD;
&#xD;
         12. of skin infection in the areas where the injection will be performed&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Patients have been diagnosed with an autoimmune disease, diabetes, rheumatoid&#xD;
             arthritis,&#xD;
&#xD;
          2. hematologic conditions predisposing to bleeding disorders or platelet dysfunction,&#xD;
             Paget's disease of femur or ilium, avascular necrosis (AVN) of the femoral head,&#xD;
             infectious arthritis, Lyme disease.&#xD;
&#xD;
          3. Previous reparative cellular/ orthobiologics /PRP injection&#xD;
&#xD;
          4. â‰¥7mm hip effusion as measured on ultrasound at the femoral neck&#xD;
&#xD;
          5. K-L Grade 4 OA x-ray documented&#xD;
&#xD;
          6. Patient has a history of alcohol or drug abuse within the six months prior to&#xD;
             enrolment in the study&#xD;
&#xD;
          7. Patients who had intra-articular treatment with corticosteroids within 6 months of&#xD;
             randomization in this study&#xD;
&#xD;
          8. Patient received more than 2 previous intra- or extra-articular corticosteroid&#xD;
             injections to the affected hip.&#xD;
&#xD;
          9. Patients who are pregnant or nursing at the time of consent&#xD;
&#xD;
         10. Patients who have had anorexia, chronic insomnia, immunocompromised state, and/ or are&#xD;
             on immunosuppressive medication&#xD;
&#xD;
         11. Neoplastic cancer within 5 years prior to screening and no evidence of recurrence,&#xD;
             except for cutaneous (basal cell and squamous cell) cancer treated with excision&#xD;
&#xD;
         12. History of chemotherapy within the past 3 years or radiation therapy to the involved&#xD;
             hip area&#xD;
&#xD;
         13. Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)&#xD;
&#xD;
         14. Patients who have had previous intervention to the hip except for labral repair/&#xD;
             reconstruction and/ or femoral neck osteoplasty or acetabular osteoplasty without&#xD;
             microfracture.&#xD;
&#xD;
         15. Additional disabilities in any of the lower limbs that would interfere with any of the&#xD;
             clinical assessments.&#xD;
&#xD;
         16. Use of NSAID 7 days prior to treatment or oral or subcutaneous corticosteroids 30 days&#xD;
             prior&#xD;
&#xD;
         17. Patients with a BMI over 35&#xD;
&#xD;
         18. Deformity or dysplasia (i.e. Legg Calve Perthes or DDH) other than FAI.&#xD;
&#xD;
         19. Patients with systemic infection, hematological conditions, malignancy, blood borne&#xD;
             diseases, allergies to lidocaine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean W Mulvaney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regenerative Orthopedics and Sports Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wesley McClure, BA</last_name>
    <phone>1-(301)-906-8294</phone>
    <email>Research@rosm.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regenerative Orthopedics and Sports Medicine</name>
      <address>
        <city>North Bethesda</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley McClure, BA</last_name>
      <phone>301-906-8294</phone>
      <email>research@rosm.org</email>
    </contact>
    <investigator>
      <last_name>Sean W Mulvaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet-rich plasma</keyword>
  <keyword>leukocyte poor platelet rich plasma</keyword>
  <keyword>PRP</keyword>
  <keyword>hip osteoarthritis</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>Regenerative orthopedics and sports medicine</keyword>
  <keyword>ROSM</keyword>
  <keyword>EmCyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

